{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T04:27:26Z","timestamp":1727238446904},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.7759\/cureus.70078","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:48:54Z","timestamp":1727182134000},"source":"Crossref","is-referenced-by-count":0,"title":["Venous Thromboembolism Prophylaxis in Patients Treated for Acute Lymphoblastic Leukemia: A Comprehensive Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Bareq S","family":"Al Lami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shad B","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif N","family":"Al-Tawil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawen","family":"Aras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blnd D","family":"Dlshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Wilya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"Slevanay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahraa","family":"Sarkawt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha","family":"Fadhel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avin","family":"Salahaddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazha","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunai","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vena","family":"Abdulwahhab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hivi","family":"Albarznji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/C2013-0-23355-9","article-title":"","author":"Hoffman R","year":"2017","unstructured":"Hoffman R, Benz E, Silberstein L, et al.. Hematology: basic principles and practice. Elsevier, 2017. 10.1016\/C2013-0-23355-9"},{"key":"ref2","article-title":"Wintrobe's clinical hematology: fourteenth edition","author":"Greer J","year":"2018","unstructured":"Greer J, Arber D, Glader B, et al.. Wintrobe's clinical hematology: fourteenth edition. Wolters Kluwer Health Pharma Solutions Ltd., 2018."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival","volume":"113","author":"Ku GH","year":"2009","unstructured":"Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009, 113:3911-7. 10.1182\/blood-2008-08-175745","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004919","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain C","year":"2020","unstructured":"Orvain C, Balsat M, Tavernier E, et al.. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020, 136:328-38. 10.1182\/blood.2020004919","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2003.10.007","article-title":"Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy","volume":"111","author":"Athale UH","year":"2003","unstructured":"Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res. 2003, 111:199-212. 10.1016\/j.thromres.2003.10.007","journal-title":"Thromb Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-11-0845","article-title":"Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation","volume":"109","author":"Lauw MN","year":"2013","unstructured":"Lauw MN, Van der Holt B, Middeldorp S, Meijers JC, Cornelissen JJ, Biemond BJ. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost. 2013, 109:633-42. 10.1160\/TH12-11-0845","journal-title":"Thromb Haemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2024)","author":"Higgins JPT","year":"2023","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2024). Cochrane, 2023."},{"key":"ref9","unstructured":"Review Manager (RevMan) [computer program] Version 5.4. (2020). https.\/\/training.cochrane.org\/online-learning\/core-software\/revman."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"1016","author":"O Brien SH","year":"2024","unstructured":"O Brien SH, Rodriguez V, Lew G, et al.. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024, 1016:2023-16. 10.1016\/S2352-3026(23)00314-9","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner J","year":"2019","unstructured":"Greiner J, Schrappe M, Claviez A, et al.. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019, 104:756-65. 10.3324\/haematol.2018.194175","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1160\/TH02-11-0283","article-title":"Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study","volume":"90","author":"Mitchell L","year":"2003","unstructured":"Mitchell L, Andrew M, Hanna K, et al.. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003, 90:235-44. 10.1160\/TH02-11-0283","journal-title":"Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711408489","article-title":"Efficacy and safety of novel anticoagulants compared with established agents","volume":"2","author":"Rybak I","year":"2011","unstructured":"Rybak I, Ehle M, Buckley L, Fanikos J. Efficacy and safety of novel anticoagulants compared with established agents. Ther Adv Hematol. 2011, 2:175-95. 10.1177\/2040620711408489","journal-title":"Ther Adv Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"41","author":"Nutescu EA","year":"2016","unstructured":"Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016, 41:15-31. 10.1007\/s11239-015-1314-3","journal-title":"J Thromb Thrombolysis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier M","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, et al.. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019, 380:711-9. 10.1056\/NEJMoa1814468","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21222","article-title":"Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia","volume":"50","author":"Meister B","year":"2008","unstructured":"Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008, 50:298-303. 10.1002\/pbc.21222","journal-title":"Pediatr Blood Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16695","article-title":"Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy","volume":"191","author":"Sibai H","year":"2020","unstructured":"Sibai H, Chen R, Liu X, et al.. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. Br J Haematol. 2020, 191:748-54. 10.1111\/bjh.16695","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier M","year":"2010","unstructured":"Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010, 152:578-89. 10.7326\/0003-4819-152-9-201005040-00008","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1258","article-title":"Anticoagulant therapy for cancer-associated thrombosis : a cost-effectiveness analysis","volume":"176","author":"Gulati S","year":"2023","unstructured":"Gulati S, Eckman MH. Anticoagulant therapy for cancer-associated thrombosis : a cost-effectiveness analysis. Ann Intern Med. 2023, 176:1-9. 10.7326\/M22-1258","journal-title":"Ann Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2248839","article-title":"Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain","volume":"26","author":"Mu\u00f1oz AJ","year":"2023","unstructured":"Mu\u00f1oz AJ, Ortega L, Guti\u00e9rrez A, et al.. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain. J Med Econ. 2023, 26:1145-54. 10.1080\/13696998.2023.2248839","journal-title":"J Med Econ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH","volume":"18","author":"Zwicker JI","year":"2020","unstructured":"Zwicker JI, Wang TF, DeAngelo DJ, et al.. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH. J Thromb Haemost. 2020, 18:278-84. 10.1111\/jth.14671","journal-title":"J Thromb Haemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293580-venous-thromboembolism-prophylaxis-in-patients-treated-for-acute-lymphoblastic-leukemia-a-comprehensive-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:48:56Z","timestamp":1727182136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293580-venous-thromboembolism-prophylaxis-in-patients-treated-for-acute-lymphoblastic-leukemia-a-comprehensive-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.70078","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}